Genetic disorders
Immune deficiencies
Breast cancer
Colon cancer
Melanoma
Cystic fibrosis
Hemophilia
Liver disease
Cardiovascular disease
Muscular dystrophy
Alzheimer's disease
Parkinson's disease
Huntington's disease
Viruses: the cornerstone of gene therapy
Viruses are living crystals
Viral genomes may be RNA or DNA
Viruses evolved from plasmids
Viruses know how to infect cells
The virus as a gene vehicle
Viruses used in gene therapy
Ashi DeSilva: a promising start
Clinical trials defined
Cells of the immune system
Adenosine deaminase (ADA)
Preliminary research
Clinical procedure for ADA gene therapy
The DeSilva clinical trial
Jesse Gelsinger: down to earth
Ornithine transcarbamylase (OTC)
Preliminary research
Clinical procedure for OTC gene therapy
The Gelsinger clinical trial
The investigation
Concluding remarks
Future prospects
Safer vehicles
Reducing immune rejection of the vector
Improved risk assessment
Redesigning human anatomy and physiology
Ethics of gene therapy
The Belmont report
Clinical trials
Physiological enhancement
Cosmetic applications
Legal issues
Regulatory agencies
The Gelsinger legal trial
International regulation
Resource center
Eucaryote cell primer
Recombinant DNA primer
The human genome project
X-linked severe combined immunodeficiency (SCID-X1)
Alzheimer's disease (AD)
Huntington's disease (HD).